Direction
Buy
Sell
Types
LMT Order
Price
QTY
Amount
--
FEMY Femasys
1.170-0.030-2.50%
Close
02/08 16:00 ET
1.1700.0000.00%
Post Mkt Price 02/08 16:00 ET
High
1.200
Open
1.200
Turnover
1.75K
Low
1.170
Pre Close
1.200
Volume
1.48K
Post-Market
5D
1D
1W
1M
1Q
1Y
Price Forecast
News
Comment
Femasys (NASDAQ:FEMY) Stock Price Down 0.8%
Femasys Inc. (NASDAQ:FEMY – Get Rating)'s stock price fell 0.8% during trading on Tuesday . The company traded as low as $1.18 and last traded at $1.21. 2,561 shares changed hands during mid-day trad
Femasys (NASDAQ:FEMY) Trading 20.4% Higher
Femasys Inc. (NASDAQ:FEMY – Get Rating)'s share price traded up 20.4% during trading on Monday . The stock traded as high as $1.24 and last traded at $1.18. 30,555 shares were traded during mid-day
12 Health Care Stocks Moving In Friday's Intraday Session
GainersPalisade Bio (NASDAQ:PALI) shares increased by 111.8% to $6.82 during Friday's regular session. The current volume of 67.8 million shares is 4351.8% of Palisade Bio's average full-day volume ov
Stocks That Hit 52-Week Lows On Wednesday
 On Wednesday, 258 companies hit new 52-week lows. Noteworthy Mentions In Today's 52-Week Lows: Amazon.com (NASDAQ:AMZN) was the largest firm on a market cap basis to set a new 52-week low.The smal
Head to Head Analysis: Akili (NASDAQ:AKLI) and Femasys (NASDAQ:FEMY)
Femasys (NASDAQ:FEMY – Get Rating) and Akili (NASDAQ:AKLI – Get Rating) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength o
Looking Into Femasys's Return On Capital Employed
Femasys (NASDAQ:FEMY) brought in sales totaling $347 thousand during Q3 according to data provided by Benzinga Pro. However, earnings decreased 13.24%, resulting in a loss of $2.98 million. In Q2, Fem
Femasys Inc. Announces Commercial Availability of Its FemCath Intrauterine Device
-- FemCath™ is the first FDA-cleared intrauterine catheter that allows for selective evaluation of a fallopian tube with contrast -- -- FemCath is used in conjunction with FemVue as a baseline diagnostic test for
Femasys (NASDAQ:FEMY) Stock Price Up 8.5%
Femasys Inc. (NASDAQ:FEMY – Get Rating) shares rose 8.5% during mid-day trading on Friday . The stock traded as high as $1.12 and last traded at $1.12. Approximately 2,795 shares changed hands during
Maxim Group Remains a Buy on Femasys (FEMY)
Femasys Holds Promotional Launch of FemCerv
Company Overview
More
Femasys, Inc. operates as a medical device company that focuses on women's healthcare. Its products include FemVue Saline-Air Device, which creates and delivers an alternating pattern of saline and air as a continuous stream, and enables physicians to assess their patients fallopian tubes, and FemChec Pressure Management Device, which limits the maximum applied pressure while performing hysterosalpingogram. The firm offers FemCerv, an endocervical curettage device to collect a non-contaminated tissue sample for cervical cancer screening. The company was founded by Kathy Lee-Sepsick in 2004 and is headquartered in Suwanee, GA.
CEO： Ms. Kathy Lee-Sepsick
Market： NASDAQ
Listing Date： 06/18/2021
Paper Trade
More
Hot List
TradeSearchNews
SymbolLatest price%Chg
Loading...
Watchlist
No Stock Yet